{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T17:25:15Z","timestamp":1762104315834,"version":"build-2065373602"},"reference-count":73,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.bulcan.2022.09.001","type":"journal-article","created":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T11:55:09Z","timestamp":1665662109000},"page":"S1-S12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"S","title":["Maladie h\u00e9r\u00e9ditaire du m\u00e9tabolisme et allogreffe de cellules souches h\u00e9matopo\u00ef\u00e9tiques\u00a0: indication, modalit\u00e9 et suivi. Recommandations de la SFGM-TC"],"prefix":"10.1016","volume":"110","author":[{"given":"Charlotte","family":"Jubert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"De Berranger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Castelle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Hugues","family":"Dalle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Ouachee-Chardin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Sevin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anais","family":"Brassier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2016","series-title":"Programme national de diagnostic et de soins\u00a0\u2013\u00a0mucopolysaccharidoses","author":"M\u00e9tabolisme GMHd","key":"10.1016\/j.bulcan.2022.09.001_bib0370"},{"issue":"4","key":"10.1016\/j.bulcan.2022.09.001_bib0375","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ymgme.2016.02.006","article-title":"Effect of anti-laronidase antibodies on efficacy and safety of laronidase enzyme replacement therapy for MPS I: a comprehensive meta-analysis of pooled data from multiple studies","volume":"117","author":"Xue","year":"2016","journal-title":"Mol Genet Metab"},{"issue":"6148","key":"10.1016\/j.bulcan.2022.09.001_bib0380","doi-asserted-by":"crossref","first-page":"1233158","DOI":"10.1126\/science.1233158","article-title":"Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy","volume":"341","author":"Biffi","year":"2013","journal-title":"Science"},{"issue":"17","key":"10.1016\/j.bulcan.2022.09.001_bib0385","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1056\/NEJMoa1700554","article-title":"Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy","volume":"377","author":"Eichler","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.bulcan.2022.09.001_bib0390","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/jimd.12388","article-title":"Metachromatic leukodystrophy: a single-center longitudinal study of 45\u00a0patients","volume":"44","author":"Fumagalli","year":"2021","journal-title":"J Inherit Metab Dis"},{"issue":"10043","key":"10.1016\/j.bulcan.2022.09.001_bib0395","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(16)30374-9","article-title":"Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1\/2\u00a0trial","volume":"388","author":"Sessa","year":"2016","journal-title":"Lancet"},{"issue":"R1","key":"10.1016\/j.bulcan.2022.09.001_bib0400","doi-asserted-by":"crossref","first-page":"R42","DOI":"10.1093\/hmg\/ddr142","article-title":"Gene therapy for leukodystrophies","volume":"20","author":"Biffi","year":"2011","journal-title":"Hum Mol Genet"},{"issue":"Pt 11","key":"10.1016\/j.bulcan.2022.09.001_bib0405","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1093\/brain\/awv250","article-title":"Brain endothelial dysfunction in cerebral adrenoleukodystrophy","volume":"138","author":"Musolino","year":"2015","journal-title":"Brain"},{"issue":"15.","key":"10.1016\/j.bulcan.2022.09.001_bib0410","article-title":"Differences in MPS I and MPS II disease manifestations","volume":"22","author":"Hampe","year":"2021","journal-title":"Int J Mol Sci"},{"year":"2021","series-title":"Programme national de diagnostic et de soins: adr\u00e9noleucodystrophie","author":"M\u00e9tabolisme CdRdLeL-ereCdRdMHd","key":"10.1016\/j.bulcan.2022.09.001_bib0415"},{"issue":"13","key":"10.1016\/j.bulcan.2022.09.001_bib0420","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1182\/blood-2014-11-608075","article-title":"Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study","volume":"125","author":"Aldenhoven","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2022.09.001_bib0425","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1750-1172-6-55","article-title":"Enzyme replacement therapy and\/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure","volume":"6","author":"de Ru","year":"2011","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"10.1016\/j.bulcan.2022.09.001_bib0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2012.07.052","article-title":"Enzyme replacement is associated with better cognitive outcomes after transplant in Hurler syndrome","volume":"162","author":"Eisengart","year":"2013","journal-title":"J Pediatr"},{"issue":"5","key":"10.1016\/j.bulcan.2022.09.001_bib0435","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1055\/s-0036-1584602","article-title":"Neurodevelopmental outcome after hematopoietic cell transplantation in inborn errors of metabolism: current considerations and future perspectives","volume":"47","author":"Boelens","year":"2016","journal-title":"Neuropediatrics"},{"issue":"6","key":"10.1016\/j.bulcan.2022.09.001_bib0440","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/bmt.2017.5","article-title":"Changes in the incidence, patterns and outcomes of graft failure following hematopoietic stem cell transplantation for Hurler syndrome","volume":"52","author":"Lum","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"1\u20132","key":"10.1016\/j.bulcan.2022.09.001_bib0445","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ymgme.2015.06.002","article-title":"Neurocognition across the spectrum of mucopolysaccharidosis type I: age, severity, and treatment","volume":"116","author":"Shapiro","year":"2015","journal-title":"Mol Genet Metab"},{"issue":"3","key":"10.1016\/j.bulcan.2022.09.001_bib0450","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s10545-017-0034-6","article-title":"Long term survival and cardiopulmonary outcome in children with Hurler syndrome after haematopoietic stem cell transplantation","volume":"40","author":"Lum","year":"2017","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"10.1016\/j.bulcan.2022.09.001_bib0455","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s10545-016-0006-2","article-title":"Mortality after hematopoietic stem cell transplantation for severe mucopolysaccharidosis type I: the 30-year University of Minnesota experience","volume":"40","author":"Rodgers","year":"2017","journal-title":"J Inherit Metab Dis"},{"issue":"10","key":"10.1016\/j.bulcan.2022.09.001_bib0460","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/j.bbmt.2017.06.020","article-title":"Hematopoietic stem cell transplantation for patients with mucopolysaccharidosis II","volume":"23","author":"Kubaski","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.bulcan.2022.09.001_bib0465","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ymgme.2012.09.004","article-title":"Long-term efficacy of hematopoietic stem cell transplantation on brain involvement in patients with mucopolysaccharidosis type II: a nationwide survey in Japan","volume":"107","author":"Tanaka","year":"2012","journal-title":"Mol Genet Metab"},{"issue":"2","key":"10.1016\/j.bulcan.2022.09.001_bib0470","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ymgme.2014.11.002","article-title":"Activities of daily living in patients with Hunter syndrome: impact of enzyme replacement therapy and hematopoietic stem cell transplantation","volume":"114","author":"Tanjuakio","year":"2015","journal-title":"Mol Genet Metab"},{"issue":"5","key":"10.1016\/j.bulcan.2022.09.001_bib0475","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jpeds.2008.11.041","article-title":"Bone marrow transplantation in children with Hunter syndrome: outcome after 7\u00a0to 17\u00a0years","volume":"154","author":"Guffon","year":"2009","journal-title":"J Pediatr"},{"key":"10.1016\/j.bulcan.2022.09.001_bib0480","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13023-015-0259-0","article-title":"Diagnosis, quality of life, and treatment of patients with Hunter syndrome in the French healthcare system: a retrospective observational study","volume":"10","author":"Guffon","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.bulcan.2022.09.001_bib0485","first-page":"62","article-title":"Early hematopoietic stem cell transplantation in a patient with severe mucopolysaccharidosis II: A 7\u00a0years follow-up","volume":"12","author":"Barth","year":"2017","journal-title":"Mol Genet Metab Rep"},{"issue":"2","key":"10.1016\/j.bulcan.2022.09.001_bib0490","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ymgme.2016.04.005","article-title":"Activity of daily living for Morquio A syndrome","volume":"118","author":"Yasuda","year":"2016","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.bulcan.2022.09.001_bib0495","first-page":"63","article-title":"Early umbilical cord blood-derived stem cell transplantation does not prevent neurological deterioration in mucopolysaccharidosis type III","volume":"18","author":"Welling","year":"2015","journal-title":"JIMD Rep"},{"issue":"9","key":"10.1016\/j.bulcan.2022.09.001_bib0500","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1080\/21678707.2016.1214572","article-title":"Current therapies for Morquio A syndrome and their clinical outcomes","volume":"4","author":"Sawamoto","year":"2016","journal-title":"Expert Opin Orphan Drugs"},{"issue":"11","key":"10.1016\/j.bulcan.2022.09.001_bib0505","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1016\/j.bbmt.2016.08.015","article-title":"Allogeneic hematopoietic stem cell transplantation in thirty-four pediatric cases of mucopolysaccharidosis\u00a0\u2013\u00a0a ten-year report from the China children transplant group","volume":"22","author":"Wang","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.bulcan.2022.09.001_bib0510","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ymgme.2015.09.011","article-title":"Hematopoietic stem cell transplantation for Morquio A syndrome","volume":"117","author":"Yabe","year":"2016","journal-title":"Mol Genet Metab"},{"issue":"1","key":"10.1016\/j.bulcan.2022.09.001_bib0515","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13023-019-1080-y","article-title":"Recommendations for the management of MPS VI: systematic evidence- and consensus-based guidance","volume":"14","author":"Akyol","year":"2019","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"10.1016\/j.bulcan.2022.09.001_bib0520","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ymgme.2010.09.010","article-title":"Clinical outcomes following hematopoietic stem cell transplantation for the treatment of mucopolysaccharidosis VI","volume":"102","author":"Turbeville","year":"2011","journal-title":"Mol Genet Metab"},{"issue":"Suppl 2","key":"10.1016\/j.bulcan.2022.09.001_bib0525","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13052-018-0566-x","article-title":"A new case report of severe mucopolysaccharidosis type VII: diagnosis, treatment with haematopoietic cell transplantation and prenatal diagnosis in a second pregnancy","volume":"44","author":"Furlan","year":"2018","journal-title":"Ital J Pediatr"},{"issue":"6","key":"10.1016\/j.bulcan.2022.09.001_bib0530","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/jmedgenet-2015-103322","article-title":"Clinical course of sly syndrome (mucopolysaccharidosis type VII)","volume":"53","author":"Montano","year":"2016","journal-title":"J Med Genet"},{"issue":"7","key":"10.1016\/j.bulcan.2022.09.001_bib0535","doi-asserted-by":"crossref","first-page":"e13278","DOI":"10.1111\/petr.13278","article-title":"Haematopoietic stem cell transplantation for mucopolysaccharidosis type VII: a case report","volume":"22","author":"Sisinni","year":"2018","journal-title":"Pediatr Transplant"},{"issue":"6","key":"10.1016\/j.bulcan.2022.09.001_bib0540","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/sj.bmt.1701141","article-title":"Treatment of MPS VII (Sly disease) by allogeneic BMT in a female with homozygous A619V mutation","volume":"21","author":"Yamada","year":"1998","journal-title":"Bone Marrow Transplant"},{"issue":"21.","key":"10.1016\/j.bulcan.2022.09.001_bib0545","article-title":"First report of a patient with MPS type VII, due to novel mutations in GUSB, who underwent enzyme replacement and then hematopoietic stem cell transplantation","volume":"20","author":"Dubot","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bulcan.2022.09.001_bib0550","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13023-015-0313-y","article-title":"Long-term outcomes after allogeneic hematopoietic stem cell transplantation for metachromatic leukodystrophy: the largest single-institution cohort report","volume":"10","author":"Boucher","year":"2015","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"10.1016\/j.bulcan.2022.09.001_bib0555","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/sj.bmt.1705581","article-title":"Early marrow transplantation in a pre-symptomatic neonate with late infantile metachromatic leukodystrophy does not halt disease progression","volume":"39","author":"Bredius","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.bulcan.2022.09.001_bib0560","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.bbmt.2013.01.010","article-title":"Neurodevelopmental outcomes of umbilical cord blood transplantation in metachromatic leukodystrophy","volume":"19","author":"Martin","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.bulcan.2022.09.001_bib0565","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1001\/jamaneurol.2016.2067","article-title":"Long-term outcome of allogeneic hematopoietic stem cell transplantation in patients with juvenile metachromatic leukodystrophy compared with non-transplanted control patients","volume":"73","author":"Groeschel","year":"2016","journal-title":"JAMA Neurol"},{"issue":"24","key":"10.1016\/j.bulcan.2022.09.001_bib0570","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1182\/blood-2016-03-708479","article-title":"Efficacy of hematopoietic cell transplantation in metachromatic leukodystrophy: the Dutch experience","volume":"127","author":"van Rappard","year":"2016","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bulcan.2022.09.001_bib0575","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1016\/j.bbmt.2018.06.020","article-title":"Long-term functional outcomes after hematopoietic stem cell transplant for early infantile Krabbe disease","volume":"24","author":"Allewelt","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"20","key":"10.1016\/j.bulcan.2022.09.001_bib0580","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1056\/NEJMoa042604","article-title":"Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease","volume":"352","author":"Escolar","year":"2005","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.bulcan.2022.09.001_bib0585","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1212\/WNL.0000000000004418","article-title":"Developmental outcomes of cord blood transplantation for Krabbe disease: a 15-year study","volume":"89","author":"Wright","year":"2017","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.bulcan.2022.09.001_bib0590","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/jon.12502","article-title":"Hematopoietic stem cell transplantation in late-onset Krabbe disease: no evidence of worsening demyelination and axonal loss 4\u00a0years post-allograft","volume":"28","author":"Laule","year":"2018","journal-title":"J Neuroimaging"},{"issue":"9","key":"10.1016\/j.bulcan.2022.09.001_bib0595","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/sj.bmt.1705984","article-title":"Sustained neurological improvement following reduced-intensity conditioning allogeneic haematopoietic stem cell transplantation for late-onset Krabbe disease","volume":"41","author":"Lim","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.bulcan.2022.09.001_bib0600","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/jnr.23914","article-title":"Challenge of phenotype estimation for optimal treatment of Krabbe disease","volume":"94","author":"Sakai","year":"2016","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.bulcan.2022.09.001_bib0605","first-page":"57","article-title":"Stem cell transplantation for adult-onset krabbe disease: report of a case","volume":"10","author":"Sharp","year":"2013","journal-title":"JIMD Rep"},{"issue":"5","key":"10.1016\/j.bulcan.2022.09.001_bib0610","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/sj.bmt.1702185","article-title":"Measurements from normal umbilical cord blood of four lysosomal enzymatic activities: alpha-L-iduronidase (Hurler), galactocerebrosidase (globoid cell leukodystrophy), arylsulfatase A (metachromatic leukodystrophy), arylsulfatase B (Maroteaux-Lamy)","volume":"25","author":"deGasperi","year":"2000","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.bulcan.2022.09.001_bib0615","doi-asserted-by":"crossref","first-page":"e363","DOI":"10.1016\/j.bbmt.2019.09.003","article-title":"Hematopoietic stem cell transplantation to treat leukodystrophies: clinical practice guidelines from the Hunter's hope leukodystrophy care network","volume":"25","author":"Page","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.bulcan.2022.09.001_bib0620","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1182\/bloodadvances.2018026963","article-title":"Immune cytopenia post-cord transplant in Hurler syndrome is a forme fruste of graft rejection","volume":"3","author":"Deambrosis","year":"2019","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.bulcan.2022.09.001_bib0625","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/j.bbmt.2020.07.030","article-title":"Guidelines for cord blood unit selection","volume":"26","author":"Politikos","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.bulcan.2022.09.001_bib0630","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.bbmt.2013.11.027","article-title":"Fludarabine and exposure-targeted busulfan compares favorably with busulfan\/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity","volume":"20","author":"Bartelink","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bulcan.2022.09.001_bib0635","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3389\/fped.2019.00433","article-title":"Hematopoietic stem cell transplantation in inborn errors of metabolism","volume":"7","author":"Tan","year":"2019","journal-title":"Front Pediatr"},{"issue":"9","key":"10.1016\/j.bulcan.2022.09.001_bib0640","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1038\/s41409-021-01378-8","article-title":"EBMT\/ESID inborn errors working party guidelines for hematopoietic stem cell transplantation for inborn errors of immunity","volume":"56","author":"Lankester","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.bulcan.2022.09.001_bib0645","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ymgme.2016.01.011","article-title":"Enzyme replacement therapy prior to haematopoietic stem cell transplantation in Mucopolysaccharidosis Type I: 10\u00a0year combined experience of 2\u00a0centres","volume":"117","author":"Ghosh","year":"2016","journal-title":"Mol Genet Metab"},{"issue":"1","key":"10.1016\/j.bulcan.2022.09.001_bib0650","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/modpathol.2008.161","article-title":"Digestive histopathological presentation of IPEX syndrome","volume":"22","author":"Patey-Mariaud de Serre","year":"2009","journal-title":"Mod Pathol"},{"issue":"6","key":"10.1016\/j.bulcan.2022.09.001_bib0655","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/sj.bmt.1705934","article-title":"Combination of enzyme replacement and hematopoietic stem cell transplantation as therapy for Hurler syndrome","volume":"41","author":"Tolar","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.bulcan.2022.09.001_bib0660","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/sj.bmt.1705401","article-title":"Haematopoietic cell transplantation (HCT) in combination with enzyme replacement therapy (ERT) in patients with Hurler syndrome","volume":"38","author":"Cox-Brinkman","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.bulcan.2022.09.001_bib0665","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/01.GIM.0000154299.22120.6A","article-title":"Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in Hurler syndrome","volume":"7","author":"Grewal","year":"2005","journal-title":"Genet Med"},{"issue":"8.","key":"10.1016\/j.bulcan.2022.09.001_bib0670","article-title":"Intravenous enzyme replacement therapy in mucopolysaccharidoses: clinical effectiveness and limitations","volume":"21","author":"Parini","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.bulcan.2022.09.001_bib0675","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.jpeds.2008.11.005","article-title":"Improved metabolic correction in patients with lysosomal storage disease treated with hematopoietic stem cell transplant compared with enzyme replacement therapy","volume":"154","author":"Wynn","year":"2009","journal-title":"J Pediatr"},{"issue":"9","key":"10.1016\/j.bulcan.2022.09.001_bib0680","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.3324\/haematol.2011.058644","article-title":"Hematopoietic stem cell transplantation improves the high incidence of neutralizing allo-antibodies observed in Hurler's syndrome after pharmacological enzyme replacement therapy","volume":"97","author":"Saif","year":"2012","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.bulcan.2022.09.001_bib0685","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1007\/s10875-014-0110-8","article-title":"Interleukin-2-inducible T-cell kinase (ITK) deficiency\u00a0\u2013\u00a0clinical and molecular aspects","volume":"34","author":"Ghosh","year":"2014","journal-title":"J Clin Immunol"},{"issue":"5","key":"10.1016\/j.bulcan.2022.09.001_bib0690","doi-asserted-by":"crossref","first-page":"e1242","DOI":"10.1542\/peds.2009-2843","article-title":"Laronidase for cardiopulmonary disease in Hurler syndrome 12\u00a0years after bone marrow transplantation","volume":"126","author":"Valayannopoulos","year":"2010","journal-title":"Pediatrics"},{"issue":"1S","key":"10.1016\/j.bulcan.2022.09.001_bib0695","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.bulcan.2019.03.006","article-title":"Children and adolescents discharge guidelines after allogeneic stem cell transplantation for healthcare professionals: Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)","volume":"107","author":"Sirvent","year":"2020","journal-title":"Bull Cancer"},{"issue":"1","key":"10.1016\/j.bulcan.2022.09.001_bib0700","doi-asserted-by":"crossref","first-page":"91e91","DOI":"10.1016\/j.bbmt.2020.08.033","article-title":"Outcome after cord blood transplantation using busulfan pharmacokinetics-targeted myeloablative conditioning for Hurler syndrome","volume":"27","author":"Lum","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"10.1016\/j.bulcan.2022.09.001_bib0705","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S1474-4422(07)70177-1","article-title":"Survival analysis of haematopoietic cell transplantation for childhood cerebral X-linked adrenoleukodystrophy: a comparison study","volume":"6","author":"Mahmood","year":"2007","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.bulcan.2022.09.001_bib0710","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1182\/blood-2003-10-3402","article-title":"Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982\u00a0to 1999","volume":"104","author":"Peters","year":"2004","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bulcan.2022.09.001_bib0715","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1182\/blood-2011-01-329235","article-title":"Outcomes after allogeneic hematopoietic cell transplantation for childhood cerebral adrenoleukodystrophy: the largest single-institution cohort report","volume":"118","author":"Miller","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bulcan.2022.09.001_bib0720","doi-asserted-by":"crossref","first-page":"e180769","DOI":"10.1001\/jamanetworkopen.2018.0769","article-title":"Potential risks to stable long-term outcome of allogeneic hematopoietic stem cell transplantation for children with cerebral X-linked adrenoleukodystrophy","volume":"1","author":"Kuhl","year":"2018","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.bulcan.2022.09.001_bib0725","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.bbmt.2018.09.036","article-title":"Survival and functional outcomes in boys with cerebral adrenoleukodystrophy with and without hematopoietic stem cell transplantation","volume":"25","author":"Raymond","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.bulcan.2022.09.001_bib0365","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1177\/0091270007313326","article-title":"Higher mycophenolate dose requirements in children undergoing Hematopoietic Cell Transplant (HCT)","volume":"48","author":"Jacobson","year":"2008","journal-title":"J Clin Pharmacol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455122003459?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455122003459?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T17:20:35Z","timestamp":1762104035000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455122003459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":73,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0007455122003459"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2022.09.001","relation":{},"ISSN":["0007-4551"],"issn-type":[{"type":"print","value":"0007-4551"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Maladie h\u00e9r\u00e9ditaire du m\u00e9tabolisme et allogreffe de cellules souches h\u00e9matopo\u00ef\u00e9tiques\u00a0: indication, modalit\u00e9 et suivi. Recommandations de la SFGM-TC","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2022.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}